Nivolumab as maintenance therapy following platinum‐based chemotherapy in 
EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial. Here, EGFR is linked to lung cancer.